Industry Context — Common BS Fingerprints in Unclear / Mixed / Unclassifiable Industry
ILUVIEN (Alimera Sciences, Inc.)
(https://iluvien.com) 📸 Data Snapshot: May 27, 2026Analyze the raw signals below. How would a machine score this business’s credibility?
Here are the exact signals captured from up to six pages of the site — the same raw inputs the evaluation engine analyzed. They are grouped by signal type so you can weigh each the way the machine does.
🏗️ Semantic Structure — heading hierarchy & page identity (Info Density · Commodity Fingerprint)
HOMEPAGE Home – ILUVIEN (https://iluvien.com)
Home – ILUVIEN
NAV_HEADER_REPEATED Contact – ILUVIEN (https://iluvien.com/contact/)
Contact – ILUVIEN
NAV_HEADER_REPEATED Important Safety Information – ILUVIEN (https://iluvien.com/isi/)
Important Safety Information – ILUVIEN
NAV_HEADER_HEADING_REPEATED_BODY Financial Assistance – ILUVIEN (https://iluvien.com/support/financial-assistance/)
Financial Assistance – ILUVIEN
📝 The Narrative — clean text per page (Info Density · Semantic Coherence)
HOMEPAGE (https://iluvien.com) Home – ILUVIEN
Skip to content Sorry, your browser doesn't support embedded videos. ILUVIEN® (fluocinolone acetonide intravitreal implant) 0.19 mg is indicated for the treatment of diabetic macular edema (DME) in patients who have been previously treated with a course of corticosteroids and did not have a clinically significant rise in intraocular pressure.ILUVIEN® (fluocinolone acetonide intravitreal implant) 0.19 mg is indicated for the treatment of diabetic macular edema (DME) in patients who have been previously treated with a course of corticosteroids and did not have a clinically significant rise in intraocular pressure.ILUVIEN® (fluocinolone acetonide intravitreal implant) 0.19 mg is indicated for the treatment of diabetic macular edema (DME) in patients who have been previously treated with a course of corticosteroids and did not have a clinically significant rise in intraocular pressure. ILUVIEN® (fluocinolone acetonide intravitreal implant) 0.19 mg is indicated for the treatment of diabetic macular edema (DME) in patients who have been previously treated with a course of corticosteroids and did not have a clinically significant rise in intraocular pressure.ILUVIEN® (fluocinolone acetonide intravitreal implant) 0.19 mg is indicated for the treatment of diabetic macular edema (DME) in patients who have been previously treated with a course of corticosteroids and did not have a clinically significant rise in intraocular pressure.ILUVIEN® (fluocinolone acetonide intravitreal implant) 0.19 mg is indicated for the treatment of diabetic macular edema (DME) in patients who have been previously treated with a course of corticosteroids and did not have a clinically significant rise in intraocular pressure. [H2] Take a journey with us [H2] Take a journey with us [H3] Wondering how to talk to your eye doctor about ILUVIEN? Ask the right questions [H2] Learn about ways to help pay for treatment with ILUVIEN [H3] ILUVIEN Patient Assistance Program [H3] ILUVIEN CoPay Program Find out more [H2] Possible Questions to Ask Your Doctor: How does diabetes affect diabetic macular edema (DME)?Are there steps I can take to help slow the progression of DME?How does recurring DME affect my vision?What are my options for treating DME and improving my vision?I have had diabetes for ____ year(s). Will this affect DME treatment types available to me?How does ILUVIEN work?Can I still get ILUVIEN even though I have another eye condition or prior eye surgery?What is the procedure for administering ILUVIEN?What type of payment or insurance coverage is available for ILUVIEN?What are the risks and possible side effects associated with ILUVIEN?What is my follow-up plan after an ILUVIEN injection? × Close Panel
SUB-PAGE · THIN (https://iluvien.com/contact/) Contact – ILUVIEN
[H1] Contact "*" indicates required fields
SUB-PAGE (https://iluvien.com/isi/) Important Safety Information – ILUVIEN
[H1] IMPORTANT SAFETY INFORMATION AND APPROVED USES [H2] Important Safety Information Do not use ILUVIEN if you have or think you might have:an infection in or around the eyes, including most viral diseases of the cornea and conjunctiva, including active herpes viral infection of the eye, vaccinia, varicella, mycobacterial infections, and fungal diseases.glaucoma with a cup to disc ratio of greater than 0.8.a hypersensitivity to any of the ingredients in ILUVIEN. WarningsInjections into the gel-like substance between the lens and retina of the eye (vitreous) are associated with a serious eye infection (endophthalmitis), eye inflammation, increased or decreased eye pressure, glaucoma, and choroidal or retinal detachments. Your eye doctor should monitor you regularly after the injection.If your eye becomes red, sensitive to light, painful, or you notice a change in vision, seek immediate care from your doctor.You may experience temporary blurred vision after receiving an injection and should not drive or use machinery until your vision has resolved.Prolonged use of corticosteroids may result in the development of glaucoma and can cause changes in vision. Your eye doctor should regularly monitor your eye pressure. You may develop increased eye pressure and it may need to be managed with eye drops or surgery.The use of corticosteroids may cause: posterior subcapsular cataracts; delay corneal wound healing after cataract surgery; corneal and scleral thinning; and bacterial, viral, or fungal infections. Let your doctor know if you have a history of herpes viral infections of the eye as corticosteroids are not recommended in these patients.If the back part of the lens of your eye is missing or torn, the ILUVIEN implant may move to the front part of the eye. Common side effects when using ILUVIEN for Diabetic Macular EdemaThe most common side effects in the eye were: cataracts, increased eye pressure, specks that float in the field of vision, eye pain, bleeding in the conjunctiva, clouding of the back of the eye’s lens capsule, eye irritation, separation of the gel-like substance inside of the eye (vitreous) from the retina, conjunctivitis, corneal swelling, foreign body sensation in eyes, itchy sensation in the eye, eye redness, damage to the optic nerve, eye discomfort, sensitivity to light, yellow or white spots on your retina, presence of white blood cells in the fluid behind the cornea, and eye discharge.The most common side effects not related to the eye were: anemia, headache, kidney failure, and pneumonia. These are not all of the possible side effects of ILUVIEN. Call your doctor or pharmacist for medical advice about side effects. You may report side effects to Alimera Sciences, Inc. at 1-844-445-8843 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.Please see full Prescribing Information. [H2] Approved Uses ILUVIEN is a prescription medicine that is an implant injected into the middle of the eye (vitreous) and is used for the treatment of:diabetic macular edema (DME) in patients who have been previously treated with a course of corticosteroids and did not have a significant increase in intraocular pressure.
SUB-PAGE (https://iluvien.com/support/financial-assistance/) Financial Assistance – ILUVIEN
[H1] Financial Assistance The ILUVIEN AccessPlus Program offers a range of financial assistance options that may help cover your specific needs. If your eye doctor prescribes ILUVIEN, the AccessPlus Program may be able to help find options to assist you with your out-of-pocket costs.* *Limitations apply. Payment assistance programs are for qualified insured and uninsured patients who are eligible for ILUVIEN. [H3] ILUVIEN CoPay Program The ILUVIEN CoPay Program provides copay assistance for eligible, commercially insured patients with out-of-pocket costs that exceed $25.† To apply for the ILUVIEN CoPay Program, you or your eye doctor can contact AccessPlus and choose option 3 when calling 1-844-445-8843. †Limitations apply. The ILUVIEN CoPay Program does not apply to patient cost sharing for the injection procedure, diagnostic tests, or other costs associated with ILUVIEN treatment. [H3] ILUVIEN Patient Assistance Program The ILUVIEN Patient Assistance Program can provide FREE treatment for qualified uninsured and rendered uninsured patients. Complete the ILUVIEN Patient Assistance Program application with your eye doctor.If you are determined eligible, you and your eye doctor will receive an approval letter indicating that you may proceed with scheduling your injection appointment. Contact AccessPlus today to learn more. Call 1-844-445-8843 (option 3) Financial Assistance Brochure [H3] Questions to ask your doctor about ILUVIEN.
🛡️ Trust Signals — reviews, proof links, trust-theatre flag (Trust & Proof)
| Page | Reviews | Proof links |
|---|---|---|
| / (home) | 3 | 0 |
| /contact/ | 3 | 0 |
| /isi/ | 3 | 0 |
| /support/financial-assistance/ | 3 | 0 |
🔗 Identity & Technical Layer — schema JSON-LD: identity chains, entity gaps (Identity & Authority)
Homepage schema
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "WebPage",
"@id": "https://iluvien.com/",
"url": "https://iluvien.com/",
"name": "Home - ILUVIEN",
"isPartOf": {
"@id": "https://iluvien.com/#website"
},
"about": {
"@id": "https://iluvien.com/#organization"
},
"primaryImageOfPage": {
"@id": "https://iluvien.com/#primaryimage"
},
"image": {
"@id": "https://iluvien.com/#primaryimage"
},
"thumbnailUrl": "https://iluvien.com/wp-content/uploads/2024/01/doc-thumb.jpeg?wsr",
"datePublished": "2024-01-11T19:17:47+00:00",
"dateModified": "2025-10-16T17:40:34+00:00",
"breadcrumb": {
"@id": "https://iluvien.com/#breadcrumb"
},
"inLanguage": "en-US",
"potentialAction": [
{
"@type": "ReadAction",
"target": [
"https://iluvien.com/"
]
}
]
},
{
"@type": "ImageObject",
"inLanguage": "en-US",
"@id": "https://iluvien.com/#primaryimage",
"url": "https://iluvien.com/wp-content/uploads/2024/01/doc-thumb.jpeg?wsr",
"contentUrl": "https://iluvien.com/wp-content/uploads/2024/01/doc-thumb.jpeg?wsr"
},
{
"@type": "BreadcrumbList",
"@id": "https://iluvien.com/#breadcrumb",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "Home"
}
]
},
{
"@type": "WebSite",
"@id": "https://iluvien.com/#website",
"url": "https://iluvien.com/",
"name": "ILUVIEN",
"description": "Patients and Caregivers",
"publisher": {
"@id": "https://iluvien.com/#organization"
},
"potentialAction": [
{
"@type": "SearchAction",
"target": {
"@type": "EntryPoint",
"urlTemplate": "https://iluvien.com/?s={search_term_string}"
},
"query-input": {
"@type": "PropertyValueSpecification",
"valueRequired": true,
"valueName": "search_term_string"
}
}
],
"inLanguage": "en-US"
},
{
"@type": "Organization",
"@id": "https://iluvien.com/#organization",
"name": "ILUVIEN",
"url": "https://iluvien.com/",
"logo": {
"@type": "ImageObject",
"inLanguage": "en-US",
"@id": "https://iluvien.com/#/schema/logo/image/",
"url": "https://iluvien.com/wp-content/uploads/2024/01/logo.svg",
"contentUrl": "https://iluvien.com/wp-content/uploads/2024/01/logo.svg",
"width": 1,
"height": 1,
"caption": "ILUVIEN"
},
"image": {
"@id": "https://iluvien.com/#/schema/logo/image/"
},
"sameAs": [
"https://www.facebook.com/ILUVIENUSA/",
"https://x.com/ILUVIEN_USA",
"https://www.youtube.com/channel/UCt7CaAU_YYbZPnlkynbTsJw",
"https://www.instagram.com/iluvien_usa/?hl=en"
]
}
]
}
/contact/
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "WebPage",
"@id": "https://iluvien.com/contact/",
"url": "https://iluvien.com/contact/",
"name": "Contact - ILUVIEN",
"isPartOf": {
"@id": "https://iluvien.com/#website"
},
"datePublished": "2024-01-11T19:24:33+00:00",
"dateModified": "2024-02-15T20:43:04+00:00",
"breadcrumb": {
"@id": "https://iluvien.com/contact/#breadcrumb"
},
"inLanguage": "en-US",
"potentialAction": [
{
"@type": "ReadAction",
"target": [
"https://iluvien.com/contact/"
]
}
]
},
{
"@type": "BreadcrumbList",
"@id": "https://iluvien.com/contact/#breadcrumb",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "Home",
"item": "https://iluvien.com/"
},
{
"@type": "ListItem",
"position": 2,
"name": "Contact"
}
]
},
{
"@type": "WebSite",
"@id": "https://iluvien.com/#website",
"url": "https://iluvien.com/",
"name": "ILUVIEN",
"description": "Patients and Caregivers",
"publisher": {
"@id": "https://iluvien.com/#organization"
},
"potentialAction": [
{
"@type": "SearchAction",
"target": {
"@type": "EntryPoint",
"urlTemplate": "https://iluvien.com/?s={search_term_string}"
},
"query-input": {
"@type": "PropertyValueSpecification",
"valueRequired": true,
"valueName": "search_term_string"
}
}
],
"inLanguage": "en-US"
},
{
"@type": "Organization",
"@id": "https://iluvien.com/#organization",
"name": "ILUVIEN",
"url": "https://iluvien.com/",
"logo": {
"@type": "ImageObject",
"inLanguage": "en-US",
"@id": "https://iluvien.com/#/schema/logo/image/",
"url": "https://iluvien.com/wp-content/uploads/2024/01/logo.svg",
"contentUrl": "https://iluvien.com/wp-content/uploads/2024/01/logo.svg",
"width": 1,
"height": 1,
"caption": "ILUVIEN"
},
"image": {
"@id": "https://iluvien.com/#/schema/logo/image/"
},
"sameAs": [
"https://www.facebook.com/ILUVIENUSA/",
"https://x.com/ILUVIEN_USA",
"https://www.youtube.com/channel/UCt7CaAU_YYbZPnlkynbTsJw",
"https://www.instagram.com/iluvien_usa/?hl=en"
]
}
]
}
/isi/
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "WebPage",
"@id": "https://iluvien.com/isi/",
"url": "https://iluvien.com/isi/",
"name": "Important Safety Information - ILUVIEN",
"isPartOf": {
"@id": "https://iluvien.com/#website"
},
"datePublished": "2024-01-11T19:36:03+00:00",
"dateModified": "2025-04-23T20:01:47+00:00",
"breadcrumb": {
"@id": "https://iluvien.com/isi/#breadcrumb"
},
"inLanguage": "en-US",
"potentialAction": [
{
"@type": "ReadAction",
"target": [
"https://iluvien.com/isi/"
]
}
]
},
{
"@type": "BreadcrumbList",
"@id": "https://iluvien.com/isi/#breadcrumb",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "Home",
"item": "https://iluvien.com/"
},
{
"@type": "ListItem",
"position": 2,
"name": "Important Safety Information"
}
]
},
{
"@type": "WebSite",
"@id": "https://iluvien.com/#website",
"url": "https://iluvien.com/",
"name": "ILUVIEN",
"description": "Patients and Caregivers",
"publisher": {
"@id": "https://iluvien.com/#organization"
},
"potentialAction": [
{
"@type": "SearchAction",
"target": {
"@type": "EntryPoint",
"urlTemplate": "https://iluvien.com/?s={search_term_string}"
},
"query-input": {
"@type": "PropertyValueSpecification",
"valueRequired": true,
"valueName": "search_term_string"
}
}
],
"inLanguage": "en-US"
},
{
"@type": "Organization",
"@id": "https://iluvien.com/#organization",
"name": "ILUVIEN",
"url": "https://iluvien.com/",
"logo": {
"@type": "ImageObject",
"inLanguage": "en-US",
"@id": "https://iluvien.com/#/schema/logo/image/",
"url": "https://iluvien.com/wp-content/uploads/2024/01/logo.svg",
"contentUrl": "https://iluvien.com/wp-content/uploads/2024/01/logo.svg",
"width": 1,
"height": 1,
"caption": "ILUVIEN"
},
"image": {
"@id": "https://iluvien.com/#/schema/logo/image/"
},
"sameAs": [
"https://www.facebook.com/ILUVIENUSA/",
"https://x.com/ILUVIEN_USA",
"https://www.youtube.com/channel/UCt7CaAU_YYbZPnlkynbTsJw",
"https://www.instagram.com/iluvien_usa/?hl=en"
]
}
]
}
/support/financial-assistance/
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "WebPage",
"@id": "https://iluvien.com/support/financial-assistance/",
"url": "https://iluvien.com/support/financial-assistance/",
"name": "Financial Assistance - ILUVIEN",
"isPartOf": {
"@id": "https://iluvien.com/#website"
},
"datePublished": "2024-01-11T19:33:10+00:00",
"dateModified": "2026-04-30T13:48:47+00:00",
"breadcrumb": {
"@id": "https://iluvien.com/support/financial-assistance/#breadcrumb"
},
"inLanguage": "en-US",
"potentialAction": [
{
"@type": "ReadAction",
"target": [
"https://iluvien.com/support/financial-assistance/"
]
}
]
},
{
"@type": "BreadcrumbList",
"@id": "https://iluvien.com/support/financial-assistance/#breadcrumb",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "Home",
"item": "https://iluvien.com/"
},
{
"@type": "ListItem",
"position": 2,
"name": "Patient & Caregiver Resources",
"item": "https://iluvien.com/support/"
},
{
"@type": "ListItem",
"position": 3,
"name": "Financial Assistance"
}
]
},
{
"@type": "WebSite",
"@id": "https://iluvien.com/#website",
"url": "https://iluvien.com/",
"name": "ILUVIEN",
"description": "Patients and Caregivers",
"publisher": {
"@id": "https://iluvien.com/#organization"
},
"potentialAction": [
{
"@type": "SearchAction",
"target": {
"@type": "EntryPoint",
"urlTemplate": "https://iluvien.com/?s={search_term_string}"
},
"query-input": {
"@type": "PropertyValueSpecification",
"valueRequired": true,
"valueName": "search_term_string"
}
}
],
"inLanguage": "en-US"
},
{
"@type": "Organization",
"@id": "https://iluvien.com/#organization",
"name": "ILUVIEN",
"url": "https://iluvien.com/",
"logo": {
"@type": "ImageObject",
"inLanguage": "en-US",
"@id": "https://iluvien.com/#/schema/logo/image/",
"url": "https://iluvien.com/wp-content/uploads/2024/01/logo.svg",
"contentUrl": "https://iluvien.com/wp-content/uploads/2024/01/logo.svg",
"width": 1,
"height": 1,
"caption": "ILUVIEN"
},
"image": {
"@id": "https://iluvien.com/#/schema/logo/image/"
},
"sameAs": [
"https://www.facebook.com/ILUVIENUSA/",
"https://x.com/ILUVIEN_USA",
"https://www.youtube.com/channel/UCt7CaAU_YYbZPnlkynbTsJw",
"https://www.instagram.com/iluvien_usa/?hl=en"
]
}
]
}
Your Diagnosis
Before revealing the machine’s verdict, predict the BS score for each signal. Higher = more BS (more fluff, less verifiable substance). Drag each slider, then submit to compare your judgment against the engine.
Stuck? Reveal the heuristic lens — how the deterministic page-auditor reads each signal (no AI, pure pattern rules)
These are the structural rules a local, deterministic auditor applies — the same lens you can use to judge each signal. They describe what to look for, not this company’s result.
Classify each sentence as substantive or hollow. Grounding markers — numbers, currencies, dates, technical units, named entities — outweigh marketing adjectives. When fluff sits right next to hard evidence, the fluff is forgiven.
Pull the main entities out of the H1, then check whether they actually recur through the body. A page that announces one thing and then talks about another drifts. Headings with no real sentences underneath read as pseudo-substance.
Count trust words (review, testimonial, rating, verified) against real outbound proof links (Google, Trustpilot, Clutch, G2, Yelp). Lots of trust language with zero verification links is trust theatre. Unlinked logo galleries count against it.
Look at how much sentence length varies. Natural writing varies its rhythm; templated or mass-produced copy is statistically uniform. Very low variation reads as commodity content — unless unique named entities break the pattern.
Inspect the JSON-LD. Is there an Organization or Person schema, and does it carry sameAs links to real external profiles (LinkedIn, socials)? Missing schema or no identity declaration signals an anonymous entity.
Want to apply this lens yourself? The free BS Indicator Chrome extension runs these heuristic checks live on any page. Bear in mind it is a single-page, deterministic tool — it relies only on pattern rules for the page in front of it and does not perform the cross-page semantic correlation this audit uses, so its readout is a starting lens, not the full verdict.
Based on 2388 businesses audited.
Unclear / Mixed / Unclassifiable Industry BS: ILUVIEN (Alimera Sciences, Inc.) (iluvien.com)
This is a low-BS, regulation-heavy pharmaceutical brochure that prioritizes legal compliance over narrative persuasion. While the schema-based review counts are a minor deceptive flag, the technical specificity of the drug data provides significant substance.
First, populate a descriptive H1 on the homepage such as ‘Long-term Treatment for Diabetic Macular Edema.’ Second, either display the three reviews mentioned in the schema or remove them to eliminate trust theatre. Third, add direct outbound links to clinical trial results or the FDA’s summary of safety and effectiveness. Finally, replace the repetitive H2 ‘Take a journey with us’ with a substance-led heading such as ‘Continuous Micro-dosing for DME Management.’
The site perfectly matches the Pharmaceutical and Healthcare industry category, specifically focusing on ophthalmic biotechnology for Diabetic Macular Edema (DME). The content is dominated by regulatory requirements, clinical indications, and safety protocols typical of FDA-regulated medical products.
“The score of 28 is primarily driven by Trust Theatre (8 points) and high Concept Repetition (5 points). The site is largely free of industry jargon and semantic drift, but the empty H1 and technical hierarchy issues in the headings added to the Information Density penalty. The high substance of the medical claims kept the score well below the 'High BS' threshold.”
This training module utilizes a snapshot of public data from ILUVIEN (Alimera Sciences, Inc.), captured on May 27, 2026, to demonstrate how machine logic evaluates different types of business narratives.
Purpose: This data is presented under “Fair Use” / “Educational Exception” for the purpose of forensic semantic analysis, allowing users to compare human intuition against machine-generated evaluations.
Notice to ILUVIEN (Alimera Sciences, Inc.): This analysis is part of a non-adversarial audit conducted by 1 Euro SEO. The results provided by 1EuroSEO are intended as professional feedback to help improve any website’s machine-readability and authority signals. The 1EuroSEO BS Detection Tool is a free tool, and anyone can test any company to see how their content is interpreted by AI models.
Any company can use the insights for free and improve its voice by comparing it to industry clichés or competitors. When a company has updated its content, it can always submit a new audit request, which will be reflected in a new current score.
To all users: You are encouraged to visit the live site at https://iluvien.com to view the most current version of its content and learn from the source what this company is about and what it offers.